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Abstract
Purpose of Review Due to the increasing numbers of radical
prostatectomies (RP) performed for prostate cancer, a substan-
tial number of patients are now suffering from post-operative
erectile dysfunction (ED). The aim of this study is to summa-
rize the current literature on surgical techniques for managing
post-prostatectomy erectile dysfunction.
Recent Findings The PubMed database was searched for
English-language articles published up to Jan 2017 using the
following search terms: “prostatectomy AND erectile dys-
function”, “prostatectomy AND penile prostheses”, and
“prostatectomy AND penile implants”. All of the studies that
evaluated medical treatment were excluded. In the last few
decades, the understanding of the anatomy of the male pelvis
and prostate has improved. This has led to significant changes
in the nerve-sparing radical prostatectomy techniques, with
the aim of preserving post-surgical erectile function (EF). In
this scenario, the prostate vascular supply and the anatomy of
the neurovascular bundles have a central role. Penile prosthe-
sis implantation is considered the third-line treatment option
for RP ED patients, and they have been reported to be a very
successful treatment with the highest patient satisfaction rate.
Summary Considering the failure of penile rehabilitation, and
the lack of evidence for accessory pudendal artery (APA)
preservation and nerve graft, nerve-sparing surgery and penile
prostheses represent, today, the only methods to permanently
and definitively preserve or erectile function after RP.
Keywords Erectile function after radical prostatectomy .
Nerve-sparing radical prostatectomy . Radical prostatectomy
outcome
Introduction
The evolution of prostate cancer management has now taken a
paradoxical turn. Large longitudinal studies investigating the
role of active surveillance have made it clear that more than 40
to 50% of prostate cancers detected in the prostate-specific
antigen (PSA) era are indolent [1]. Despite these findings,
thousands of asymptomatic men suffering from a potentially
harmless disease still undergo aggressive surgical treatment,
and as a result, prostate cancer survivors are at risk of iatro-
genic erectile dysfunction (ED). It has been postulated that
only 10 to 23% of men aged below 60 years regain their
baseline potency after bilateral nerve-sparing radical prosta-
tectomy (NSRP) [2–4]. The use of robot-assisted radical pros-
tatectomy (RARP) has not significantly reduced these post-
operative ED rates [5]. A recent prospective trial comparing
RARP to open retropubic radical prostatectomy (RRP)
showed that only 29.6% of patients did not suffer from ED
at 1 year following open RRP compared with 25.3% after
RARP, despite RARP patients having a better performance
status and more likely to undergo a nerve-sparing procedure
[5]. Surprisingly, these rates from a real-life setting are tem-
pering the initial enthusiasm about the functional outcomes of
anatomical radical prostatectomy that has been growing over
the past two decades.
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This scenario is further complicated by the widespread use
of various penile rehabilitation protocols, despite this being
short of a solid evidence base [6]. In a survey conducted by
the International Society for Sexual Medicine (ISSM) mem-
bers from 41 countries, over 95% routinely prescribed phos-
phodiesterase type 5 inhibitors (PDE5i) to their prostatectomy
patients, as part of a penile rehabilitation protocol [7]. For
patients wishing to maintain the ability to have sexual inter-
course and in whom pharmacological options have failed,
end-stage treatment using penile prostheses surgery is an
option.
The aim of the present study was to review the current
surgical treatments for ED after radical prostatectomy.
Methods
The PubMed database was searched for English-language ar-
ticles published up to Jan 2017 using the following search
terms: “prostatectomy AND erectile dysfunction”, “prostatec-
tomy AND penile prostheses”, and “prostatectomy AND pe-
nile implants”. This review is primarily focused on the litera-
ture published within the past 10 years, although older papers
closely related to this topic are also included. The present
review evaluated only selected studies, evaluating the surgical
therapy for erectile dysfunction after radical prostatectomy.
All of the studies that evaluated medical treatment were
excluded.
Erectile Dysfunction After Radical Prostatectomy:
How Big Is the Problem?
In the last decades, several studies have investigated the
incidence of ED following RP with different and some-
times conflicting results. Factors such as the different
classification and evaluation of EF, patient selection
criteria, the surgical technique used and the different
penile rehabilitation treatment account for this wide var-
iability. EF recovery rates after an open radical prosta-
tectomy have been reported to range from 31 to 86%
[8]. Equally, potency rates for laparoscopic RP (LRP)
have been showed to range from 42 to 76% [9].
More recently, Ficarra et al. published a meta-
analysis of a RARP series and reported potency recov-
ery rates of 32 to 68%, 50 to 86%, 54 to 90% and 63
to 94% at 3, 6, 12 and 24 months after surgery, respec-
tively [10••]. The study analysed 15 case series, 6 stud-
ies comparing different techniques in the context of
RARP, 6 studies comparing RARP with RRP and 4
studies comparing RARP with LRP [10••].
Pathophysiology of Post-prostatectomy ED: Is It
a Neuronal Problem?
Penile erection is based on neurovascular pathways orchestrat-
ed by psychological, emotional and hormonal factors where
the interplay both neuronal and vascular components are cru-
cial and indispensable. A penile erection requires neurotrans-
mitters, such as nitric oxide (NO) and Prostaglandins, released
by the cavernous nerve (CN) terminals, which provide para-
sympathetic innervation to the corpora cavernosa. These neu-
rotransmitters induce the relaxation of the smooth muscle of
the arteries and of the cavernosal smooth muscle [11].
The CN terminals arise from the pelvic plexus that is locat-
ed within the fibro-fatty plane between the bladder and the
rectum, and they run in close vicinity to the tips of the seminal
vesicles along the dorsolateral aspect of the prostate, between
the capsules of the prostate. These fibers run together with
blood vessels and comprise the neurovascular bundles
(NVBs) as described by Walsh et al. [12, 13•, 14, 15].
Erectile dysfunction after non-nerve-sparing radical pros-
tatectomy is an inevitable consequence of the deliberate or un-
wanted transection of the CN.
In contrast, erectile dysfunction after nerve-sparing radical
prostatectomy (NSRP) is a complex mechanism and still not
completely understood. However, it is now clear that age co-
morbidities such as pre-operative erectile function are inde-
pendent prognostic factors for the recovery of erectile function
following surgery [16–18].
A few days after nerve-sparing surgery, ED is a result of
iatrogenic functional damage (traction injury, diathermy) to
the periprostatic neurovascular bundle, which results in
neuropraxia which is evident immediately after prostatectomy
with loss of nocturnal and sexually stimulated erections.
Urologists and patients may note moderate erectile activity
shortly after surgery, such as at the time of catheter manipulation
or removal. These events may bring about high hopes for recov-
ery of erectile function, but the nerves are partially conductive
until the ensuing Wallerian degeneration has set in several days
following the neuropraxia. The resulting denervation of the cor-
pora cavernosa results in a decrease in the rate and quality of
early morning and nocturnal erections, and thus promotes persis-
tent cavernous hypoxia, as oxygenated blood is mainly supplied
during erectile activity [19–21]. Both in vitro and in vivo studies
support the theory that penile hypoxia results in collagen accu-
mulation, smooth-muscle apoptosis and ultimately cavernosal
fibrosis. Finally, these changes within the corpus cavernosum
contribute to venous leakage and permanent ED, even if the
normal function of the nerves return [22].
It has been postulated that another mechanism involved in
post-prostatectomy ED may be the injury of the accessory
pudendal arteries [23], which have been described in up to
75% of patients, and could lead to the development of penile
hypoxia [23].
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Finally, recent results from Salamanca’s group [23] have
shown that neurogenic contractile responses (sympathetic) are
increased in the corpus cavernosum (CC) of rats following
cavernous nerve injury and in cavernosal tissues from men
suffering with post-RP ED. This is simultaneous to a profound
impairment of neurogenic relaxant responses that result in a
marked imbalance in the neurogenic control of penile smooth
muscle tone favouring contractile input over relaxant drive,
thus antagonizing the erectile process. The author concluded
that alpha-adrenergic modulation, especially selective α1A-
blockade, improves erectile and cavernosal functions after
BCNI [24••].
Surgical Management of Erectile Dysfunction
In the last couple of decades, the anatomy of the male pelvis
and prostate has improved. This has led to significant changes
in the nerve-sparing radical prostatectomy techniques, with
the aim of preserving post-surgical erectile function (EF). In
this scenario, the prostate vascular supply and the anatomy of
the NVBs have a central role [13•].
Prostate Arterial Supply: Artery-Sparing Surgery
Myth or Reality?
In 35 to 56% of cases, the prostate arteries arise from the
internal pudendal artery [24••]. The common gluteal pudendal
trunk is the next most frequent origin (15–28%), followed by
the obturator artery and the inferior gluteal artery [13•]. Two
principal bifurcations of the prostatic artery can be identified
as follows: a posterior pedicle and an anterior pedicle at the
level of the lateral side of the prostate, reaching the prostate
apex. At this level, the anterior capsular prostate branches are
responsible for the ancillary penile blood supply [13•]. The
intraoperative preservation of these structures may be respon-
sible for preservation of post-surgical EF.
The penile arterial blood supply is derived exclusively from
the internal pudendal artery (IPA) or from the IPA and an
anatomical variant known as the accessory pudendal artery
(APA) or from the APA alone [23, 25–27].
The APA is defined as any artery located in the
periprostatic region running parallel to the dorsal vascular
complex and extending caudal toward the anterior perineum.
A recent meta-analysis, [28] evaluating 23 studies, reported
that the APAwas present in 28.5% of patients. When present,
unilateral accessory pudendal arteries were most common
(pooled prevalence estimate 72.5%), or they were present on
the right or the left side (pooled prevalence estimate 48.0 or
52.0%, respectively). They were most commonly originating
from the obturator artery and the inferior vesical artery (pooled
prevalence estimate 48.9 and 29.6%, respectively). The most
common type was the apical accessory pudendal arteries
(pooled prevalence estimate 60.9%).
Numerous reports have shown that an injury to the APA
can induce vasculogenic ED. Conversely, Box et al. recently
evaluated the consequence of damaging the APA in 200 pa-
tients treated with RARP; they reported that 19 patients had an
injury of the APA. Surprisingly, 18 of them reported post-
prostatectomy EF recovery [29].
More evidences are required to assess whether APA pres-
ervation can improve the EF outcome after radical
prostatectomy.
Neurovascular Bundles: the Truth Is
Between the Layers
The neuronal supply to the corpora cavernosa originates from
the pelvic plexus and transgresses the lateral aspect of the
bladder neck passing posterolaterally to the tip of seminal
vesicles [13•]; based on this anatomical aspect, it can be pos-
tulated that the preservation of the tip of the seminal vesicles
may aid the recovery rate for EF. However, no scientific evi-
dence is available for this. A prospective controlled study,
including 52 patients (followed up for 6 months), showed that
a seminal vesicle tip-sparing technique may preserve pelvic
innervation and reduce urinary incontinence. No data on EF
recovery rates were reported in this study [12]. Furthermore
randomized studies are necessary to evaluate the impact of
seminal vesicle-sparing radical prostatectomy on restoration
of urinary continence.
NVB fibers are contained in a multi-layered fascia that can
be either fused or separated from the prostatic capsule; the
relationship between this fascia, known as the periprostatic
fascia (PPF) and the NVB, has been extensively investigated
with the intent to develop a NS technique able to preserve the
largest number of cavernous fibers [13•]. The multi-layered
character of the PPF allows several degrees of dissection with
the intent of leaving a more or less thick tissue layer on the
prostate as a safety margin. This anatomical characteristic lets
the surgeon, despite individual patient variation, to choose the
degree of NS dissection based on the risk of extraprostatic
extension of the tumour [13•].
In the past, three different dissection planes had been de-
scribed: an intrafascial, interfascial and extrafascial plane
(Table 1) [30]. Successively, a new classification was de-
scribed by Montorsi et al. proposing “full, partial and mini-
mal” NS techniques as matching to intrafascial, interfascial
and “sub” extrafascial dissections, respectively (Table 1) [31].
In 2011, Tewari et al. reported a new 4-degree NS approach
[32], taking as a landmark the veins located on the lateral
aspects of the prostate. In this retrospective study, 2317 pa-
tients were evaluated. All the patients had robotic prostatecto-
my by a single surgeon at a single institution between January
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2005 and June 2010 [32]. The author showed that there was a
significant difference across different NS grades in terms of
the percentages of patients who had intercourse and returned
to baseline sexual function (P < 0.001), with those that
underwent NS grade 1 having the highest rates (90.9 and
81.7%) as compared to NS grades 2 (81.4 and74.3%), 3
(73.5 and 66.1%) and 4 (62 and 54.5%) (Table 1) [32].
Schatloff et al. [33] described a 5-degree dissection using
as a landmark the artery (LA) running along the lateral aspect
of the prostate, on the medial aspect of the NVB. The LA can
be recognized, intraoperatively, in up to 73% of cases. The
authors demonstrated that a higher NSS was significantly cor-
related with a decreasing area of residual nerve tissue on pros-
tatectomy specimens (P < 0.001); no data on erectile function
were reported (Table 1) [33].
Currently, no consensus exists regarding the possibility of a
higher incidence of post-operative ED associated with more
extended PLNDs.
Past vs Future, Open vs Robotic: Is There a Real
Difference Between the Techniques?
Despite the number of studies available in the literature, the
comparison of EF outcomes between open and minimally
invasive surgery (laparoscopic and robotic techniques) is very
difficult to perform owing to a lack of standardized method-
ology and because a lot of the evidence is derived from retro-
spective studies. Ficarra et al. in a meta-analysis on RP series
up to 2012, including a cumulative analysis of records from
open radical prostatectomy (ORP) versus RARP series,
showed a significant benefit in favour of RARP, with a risk
reduction for ED of 23.6% [10••].
However, in the last decades, several prospective random-
ized clinical trials were published. Tewari et al. in 2003 re-
ported the results of a single-institution, prospective and
unrandomized clinical trial including 100 patients undergoing






Intrafascial dissection of the NVB is
considered a dissection that follows a
plane on the prostate capsule, remaining
medial or internal to the PF at the
anterolateral and posterolateral aspect of




Interfascial dissection of the NVB is
considered a dissection outside or lateral
to the PF at the anterolateral and
posterolateral aspects of the prostate
combined with a dissection medial to the
NVB at the 5-o’clock and 7-o’clock
positions or the 2-o’clock and 10-o’clock
positions of the prostate in axial section
Extrafascial
dissection
Extrafascial dissection of the NVB (non-NS)
is considered a dissection-carried lateral to
the LAF and posterior to the PPF/SVF. In
this case, the NVB running along the
posterolateral aspect of the prostate is
completely resected with LAF, PF, and




Full Full dissection of the NVB is considered a
dissection between the prostatic capsule
and the multilayer tissue of the prostatic
fascia
Partial Partial dissection of the NVB is considered a
dissection within the multilayer tissue of
prostatic fascia
Minimal Minimal dissection of the NVB is considered
a dissection aimed to preserve only the
cavernous nerves running at the
posterolateral surface of the prostate
Tewari et al.
2011 [32]
Grade 1 Grade 1 dissection of the NVB is considered
a dissection of the Denonvilliers’ and
lateral pelvic fascia (LPF) just outside the
prostatic capsule.
Grade 2 Grade 2 dissection of the NVB is considered
a dissection through the Denonvilliers’
(leaving deeper layers on the rectum), and
LPF is taken just outside the layer of veins
of the prostate capsule
Grade 3 Grade 3 dissection of the NVB is considered
a dissection through the outer
compartment of the LPF (leaving some
yellow adipose and neural tissue on the
specimen), excising all layers of
Denonvilliers’ fascia
Grade 4 Grade 4 dissection of the NVB (non-NS) is
considered a dissection of the LPF and
Denonvilliers’ fascia containing most of
the periprostatic neurovascular tissue
Schatloff et al.
2012 [33]
Grade 5 Grade 5 (≥ 95%) dissection of the NVB is
considered a dissection performed medial
to LA just outside the prostatic fascia at
the pearly areolar tissue between the
prostate and the NVB
Grade 4 Grade 4 (75%) dissection of the NVB is
considered a dissection performed using a
sharp dissection at a plane between the LA
and the prostatic capsule across the
NVB—not at the pearly areolar plane, as
in the case of a complete NS
Grade 3 Grade 3 (50%) dissection of the NVB is
considered a dissection at the artery’s
Table 1 (continued)
Author Classification Description
lateral aspect; therefore, the LA is clipped
at the level of the prostatic pedicle
Grade 2 Grade 2 (< 50%) dissection of the NVB is
considered a dissection performed several
millimeters lateral to the artery, following
the prostatic contour
Grade 1 Grade 1 (0%) dissection of the NVB
(non-NS) is considered a dissection
performed by sequentially clipping below
the prostate across the NVB. The prostate
is lifted up and only rotated when
approximating the apex as the pelvis gets
narrow and the NVB curves in the
direction of the perineum
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ORP and 200 undergoing RARP. After RARP, patients
achieved continence and return of erections more quickly than
after ORP (160 vs 44 and 180 vs 440 days, both P < 0.5). The
median return to intercourse was 340 days after VIP, but after
RRP, half of the patients have yet to resume intercourse at
700 days (P < 0.05) [34].
Similarly, Haglind et al. showed, at 12 months following
surgery, a significant benefit in favour of RARP, in a
multicentre prospective unrandomized study including 778
ORP patients and 1847 RARP patients [5].
More recently, a sub-analysis of the REACTT trial con-
ducted to compare once-daily tadalafil, on-demand tadalafil
and placebo for penile rehabilitation showed that the odds of
achieving EF recovery at the end of the drug-free washout
period were twice as high for RARP compared to ORP, but
no difference was reported between LRP and ORP patients.
The same results were also published by Magheli et al. show-
ing, in a comparative analysis between LRP and ORP, no
difference between the two groups in terms of post-operative
EF [35].
Few studies have compared the sexual outcome between
LPR and RARP with conflicting results. Ficarra et al. showed,
in a meta-analysis [36], no statistical difference when compar-
ing EF recovery rate between LRP and RARP. These results
are in contrast with a recent prospective randomized study
conducted on 128 patients treated with either LRP or RARP
using a BNS approach. In this study, RARP patients exhibited
a higher rate of return to baseline IIEF-EF scores than LRP
patients.
Taken together, this data shows a benefit in terms of EF
recovery for RARP patients in comparison to those treated
with laparoscopic techniques or open surgery; however, re-
cently published large population-based studies comparing
ORP and RARP have reported conflicting data [37–39].
Penile Prosthesis: Is it the Best Solution?
According to the EAU guidelines on Male Sexual
Dysfunction [40], penile prosthesis implantation is considered
the third-line treatment option for ED patients after first- and
second-line pharmacological options have been exhausted.
Currently, there are two types of penile prostheses: inflat-
able and malleable types. The inflatable penile prostheses can
be subdivided into two- and three-piece devices. IPP is consid-
ered a superior option compared to a malleable prosthesis as it
produces penile rigidity and flaccidity that closely replicates a
normal penile erectile function and is easier to conceal [41].
In the RP scenario, patients undergoing NNS or NS surgery
for PCa may benefit from penile prosthesis surgery after the
failure of other treatment options, and it has also been shown
to be safe in patients who have undergone RP or RT for PCa
[40].
Penile prostheses have been reported to be a very success-
ful treatment with the highest patient satisfaction rate, up to
90% [41–44].
The impact of penile prosthesis surgery extends beyond
sustaining penile rigidity as it also includes favourable psy-
chosocial outcomes. Recently, Bettocchi et al. have reported
greater partner satisfaction rate after penile implant procedure
[45].
Penile prosthesis surgery does not affect the continence
recovery rates after RP although a small study has shown an
improvement [46]. In addition, implantation of a penile pros-
thesis does not preclude later artificial sphincter or urethral
sling surgery. Moreover, the two procedures may also be per-
formed simultaneously [47, 48].
Despite excellent patient and partner satisfaction rates and
safety profiles, penile prostheses appear to be underused in the
RRP group [49].
In 2005 for instance, Stephenson et al. [50] reported data
from the Surveillance Epidemiology and End Results cancer
registry, showing that only 1.9% of patients treated with either
RP or RT underwent penile prosthesis surgery. More recently,
Tal et al. [49] showed a lower utilization rate in a SEER pop-
ulation comprising 68,558 subjects, including 52,747 who
had RT and 15,811 who had RP as primary prostate cancer
treatment. The penile implant utilization rate was 0.8% for the
entire group, 0.3% for the RT group and 2.3% for the RP
group. Younger age, and African American or Hispanic race,
initial treatment modality and being unmarried are the most
important predictors of penile implant utilization [49].
Nerve Graft After Radical Prostatectomy
Despite the advance in NS techniques, the resection of the
NVB is still sometimes necessary to accomplish an adequate
cancer-free margin. Additionally, iatrogenic injury to the pros-
tatic nerves may occur during RP irrespective of the technique
used.
Several basic science studies in rats have shown that the
cavernous nerves can be replaced with nerve grafts with the
intent to restore EF [50–53]. Once again, creative researchers
and surgeons started thinking about the possibilities and tested
this modality in the clinical setting. Immediate interpositional
nerve grafting, using autologous sural or genitofemoral
nerves, of the prostatic plexus can be performed for amelio-
rating post-RP urinary continence and EF after nerve resection
or damage [53–63]. Although different studies have demon-
strated the feasibility of immediate nerve reconstruction after
RP, clinical outcomes have been variable, and few studies
have examined patients with long-term follow-up or in com-
parison with control groups [55–64]. Furthermore, results of a
well-designed randomized controlled trial demonstrated no ben-
efit of unilateral nerve grafting after prostatectomy [54]. As a
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result, these developments greatly tempered the enthusiasm for
cavernous nerve reconstruction, and nerve grafting has
now been largely abandoned and it is now considered an ex-
perimental procedure.
However, in the last decades, a new Bio-graft has been
tested with promising results.
Patel et al. [64] recently showed that dehydrated human
amnion/chorion membrane allograft nerve wrap around the
NVB accelerates early return to continence and potency fol-
lowing robot-assisted radical prostatectomy.
New Perspective
Stem Cell
Stem cells (SCs) are defined by their self-renewal capability
and differentiation potential to other cell lines. These charac-
teristics are responsible for the maintenance of the SC popu-
lation and the potential for tissue or organ regeneration. SCs
are classified according to their differential potential in totipo-
tent, pluripotent, multipotent, progenitor or precursor cells
[65, 66].
Embryonal SCs (ESC) are pluripotent SCs. They can dif-
ferentiate into cells from all germinal layers. Multipotent SCs
can be isolated from different adult tissues and differentiate
into any cell type within their own germinal layer.
Adult mesenchymal stem cells (MSCs) are classified as
multipotent stem cells which are able to differentiate into sev-
eral subtypes of mesenchymal cells. Until recently, this prop-
erty had only been studied for its direct medical implications
and therapeutic uses [67, 68]. However, MSCs release a wide
spectrum of regulatory and trophic factors (growth factors,
cytokines and chemokines). This suggests a paracrine effect
as “site-regulated drugstores” in vivo and can influence tissue
even if they do not engraft or differentiate [69–72]. In the last
few decades, researchers have tried applying SCs by exploiting
their immune-regulatory properties to several therapeutic sce-
narios [69]. A few examples include graft-versus-host disease
(GVHD) in bone marrow transplantation, multiple sclerosis,
brain and spinal cord injury, arthritis, myocardial infarction
and Crohn’s disease. Not surprisingly, SC treatment is also
one of the up-and-coming curative treatment options for ED
[69–72].
In 2004, Bochinski et al. [73] first tested the injection of
green fluorescent protein-labelled ESC either into the corpus
cavernosum or to the major pelvic ganglion (MPG) in the rat
model of radical prostatectomy with cavernous nerve injury
(CNI). Erectile function improved significantly in the treated
animals compared to the controls [73].
The efficacy of bone marrow SCs (BMSCs) was tested by
Kendirci et al. [74]. In this study intracavernosal BMSCs in-
jection were performed in rats after CNI. Erectile response to
cavernous nerve stimulation (CNS) was partially restored at
4 weeks [74].
Albersen et al. [75] showed that the administration of
ADSC-derived lysate in the CNI rat model showed improved
responses to CNS compared with rats injected with adipose-
derived stem cells (ADSCs). Interestingly, both ADSC and
lysate partly restored smooth muscle content and decreased
fibrosis in the corpus cavernosum, most importantly, neuronal
nitric oxide. After these pioneering studies, several preclinical
researchers evaluated the efficacy of SCs in rat model of
nerve-sparing prostatectomy with positive results [75].
To progress toward clinical translation, Yiou et al. [76], in
phase 1 trial, tested the efficacy of intracavernous injection of
autologous BMSCs in 12 patients with post-prostatectomy
ED. The patients were divided into four groups treated with
escalating doses of BMSCs [76].
Only 4 of 12 men had nerve-sparing surgery. Patients re-
ported subjective improvement in the Erectile Hardness Score.
Doppler ultrasound showed an improvement when combined
with pharmacotherapy. Importantly, no significant adverse re-
actions were reported after 6 months [76].
A similar clinical study using adipose stromal vascular
fraction (SVF) [77] was conducted byHaahr et al. The adipose
SVF provides a rich source of ADSCs and can easily be iso-
lated from human adipose tissue, representing a viable alter-
native to bonemarrowmesenchymal stem cells [77]. The SVF
can be easily isolated through enzymatic digestion of aspirated
adipose tissue, and it does not need to be cultured. Seventeen
subjects suffering from ED after RP were enrolled. Adipose
tissue was collected by liposuction under general anaesthesia
and immediately processed (Celution 800/CRS system, Cytori
Therapeutics, San Diego, CA, USA). Five patients reported
minor events (Clavien-Dindo grade I) related mostly to the
liposuction procedure. During the follow-up of this study, 8
of 17 patients engaged in successful sexual intercourse [77].
Further, large randomized studies are necessary to prove
the real efficacy of stem cells treatment for ED after RP.
Conclusion
Prostate cancer treatment has continued to progress resulting
in favourable oncological outcomes. In this context, the qual-
ity of life of these patients, undergoing radical prostatectomy,
has become of primary importance as part of their cancer
survivorship. Although satisfactory results have been
achieved for post-RP urinary continence, the same goals have
not been replicated for erectile dysfunction after RP.
In this context, clinicians should be aware of the correct
approaches to assist post-RP EF recovery.
Pathways to prevent post-RP ED clearly encompass all
steps of the comprehensive clinical management of every
PCa patient, including pre-operative, intraoperative and post-
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operative settings. Indeed, candidates for various surgical
strategies should be carefully selected according to the base-
line oncological and functional factors. Moreover, the advent
of minimally invasive RP procedures has led to improved
general anatomic knowledge and to the development of more
conservative NS surgical techniques, thus facilitating a signif-
icant overall improvement in functional post-operative
outcome.
Considering the failure of penile rehabilitation and the lack
of evidence for APA preservation and nerve graft, nerve-
sparing surgery and penile prostheses represent, today, the
only methods to permanently and definitively preserve erectile
function after RP.
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